1. HOME
2. Research Insight
3. Abbott Laboratories (US) F. Hoffman-La Roche (Switzerland) and QIAGEN (Germany) are Leading Players in the Hemato Oncology Testing Market

The global Hemato oncology testing market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.

The market is competitive. The major players operating in hemato oncology testing market are Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden), Cancer Diagnostics (US).

To know about the assumptions considered for the study download the pdf brochure

ABBOTT LABORATORIES (US)

Abbott Laboratories was the leading player in the hemato-oncology testing market in 2021. In Abbott’s worldwide Diagnostics business, sales increased by 42.7% in 2021. It offers kits for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The company has been able to introduce innovative products, such as Abbott RealTime IDH1 and Abbott RealTime IDH2 assay kits, into the market. Abbott has a strong presence in the US, where it registered USD 7,129 million in 2021 for the Diagnostics business.

F. HOFFMANN-LA ROCHE (SWITZERLAND)

F. Hoffmann-La Roche was the second-largest player in the hemato-oncology testing market in 2021. The company offers a full range of tests for the diagnosis of hemato-oncology cancers, such as leukemia, lymphoma, myeloma, and other cancers. Its strong presence across the globe, robust distribution channels, and brand image help the company maintain a dominant position in the hemato-oncology testing market. Roche has been focusing on emerging markets in recent years, with specific focus on the Asia Pacific. The company has also registered USD 4,347 million in overall sales from the Asia Pacific market in 2021 for its Diagnostic division.

QIAGEN (GERMANY)

QIAGEN was the third-largest player in this market in 2021. The company offers the RT2 Profiler PCR arrays for testing hemato-oncology cancers. It focuses on organic growth strategies to maintain its leading position in the market. In 2021, the company launched the QIAact Myeloid DNA UMI Panel for hemato-oncology cancer research. The company also focuses on R&D to introduce innovative products into the market. The company invested approximately 88% of its total revenue in consumables and related revenue.

Related Reports:

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User - Global Forecast to 2027

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]